NCT02647294View on ClinicalTrials.gov

Polyunsaturated Fatty Acids in Patients With NAFLD.

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
NAFLD
Interventions
DIETARY_SUPPLEMENT

Maxicor

Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).

OTHER

Placebo

Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).

Trial Locations (1)

128 08

General University Hospital, Prague

All Listed Sponsors
lead

General University Hospital, Prague

OTHER

NCT02647294 - Polyunsaturated Fatty Acids in Patients With NAFLD. | Biotech Hunter | Biotech Hunter